Beam Therapeutics Inc.
NASDAQ:BEAM
19.94 (USD) • At close September 8, 2025
 Overzicht | Financiële gegevens
 | Bedrijfsnaam | Beam Therapeutics Inc. | 
| Symbool | BEAM | 
| Munteenheid | USD | 
| Prijs | 19.94 | 
| Beurswaarde    |  2,017,170,280 | 
| Dividendpercentage    |  0% | 
| 52-weken bereik | 13.525 - 35.25 | 
| Industrie | Biotechnology | 
| Sector | Healthcare | 
| CEO | Mr. John M. Evans M.B.A. | 
| Website | https://www.beamtx.com | 
An error occurred while fetching data.
Over Beam Therapeutics Inc.
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor 
 Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)









